(Q43748718)

26 November 2017

title

Cerebrotendinous xanthomatosis: 11-year treatment with chenodeoxycholic acid in five patients. An electrophysiological study (English)

1 reference

cerebrotendinous xanthomatosis

26 November 2017

1 reference

1 reference

Mondelli M

1

1 reference

26 November 2017

Sicurelli F

2

1 reference

26 November 2017

Scarpini C

3

1 reference

26 November 2017

Dotti MT

4

1 reference

26 November 2017

Federico A

5

1 reference

26 November 2017

publication date

1 September 2001

1 reference

Journal of the Neurological Sciences

26 November 2017

published in

1 reference

26 November 2017

volume

190

1 reference

26 November 2017

issue

1-2

1 reference

26 November 2017

page(s)

29-33

1 reference

Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis.

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900563-9

Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900563-9

Evoked potentials in cerebrotendinous xanthomatosis and effect induced by chenodeoxycholic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900563-9

Somatosensory and motor evoked potentials in the assessment of cerebrotendinous xanthomatosis before and after treatment with chenodeoxycholic acid: a preliminary study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900563-9

Chenodeoxycholic acid inhibits increased cholesterol and cholestanol synthesis in patients with cerebrotendinous Xanthomatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900563-9

Cerebrotendinous xanthomatosis: clinical, electrophysiological and nerve biopsy findings, and response to treatment with chenodeoxycholic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900563-9

Treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900563-9

Cerebrotendinous xanthomatosis (CTX): a clinical survey of the patient population in The Netherlands.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900563-9

Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900563-9

Treatment of cerebrotendinous xanthomatosis: effects of chenodeoxycholic acid, pravastatin, and combined use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900563-9

The interpretation of electromyographic responses to electrical stimulation of the motor cortex in diseases of the upper motor neurone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900563-9

Magnetic and electrical transcranial brain stimulation: physiological mechanisms and clinical applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900563-9

Pathophysiology of spasticity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900563-9

Electrophysiological studies in cerebrotendinous xanthomatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900563-9

Magnetic resonance imaging in cerebrotendinous xanthomatosis: a prospective clinical and neuroradiological study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900563-9

Neuroaxonal pathology of central and peripheral nervous systems in cerebrotendinous xanthomatosis (CTX).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900563-9

The neuropathology of cerebrotendinous xanthomatosis revisited: a case report and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900563-9

Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900563-9

Treatment and follow-up of children with cerebrotendinous xanthomatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900563-9

Cerebrotendinous xanthomatosis: treatments with simvastatin, lovastatin, and chenodeoxycholic acid in 3 siblings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900563-9

Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900563-9

Treatment of cerebrotendinous xanthomatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900563-9

Muscle mitochondrial changes in cerebrotendinous xanthomatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2801%2900563-9

10.1016/S0022-510X(01)00563-9

7 January 2021

Identifiers

DOI

1 reference

26 November 2017

1 reference